Plasma hTERT mRNA discriminates between clinically localized and locally advanced disease and is a predictor of recurrence in prostate cancer patients.

Autores de IIS La Fe

• Jose María Martinez Jabaloyas

  Autor

• María José Herrero Cervera

  Autor

• Salvador F Aliño Pellicer

  Autor

• Francisco José Dasí Fernández

  Autor

Participantes ajenos a IIS La Fe

• March-Villalba JA
• Santamaría J

Abstract

Since the introduction of prostate-specific antigen (PSA) testing, new prostate cancer (PCa) patients are diagnosed earlier and most have localized and locally advanced disease. Current diagnosis methods lack specificity and sensitivity, leading to overdiagnosis and overtreatment of patients with low-risk organ-confined localized disease. Therefore, new non-invasive molecular tools are needed to discriminate between localized and locally advanced disease.